喵ID:8ww6wj免责声明

MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer.

基本信息

DOI:
10.1016/j.bbrc.2009.07.143
发表时间:
2009-10-23
影响因子:
3.1
通讯作者:
Nana-Sinkam, Serge P.
中科院分区:
生物学4区
文献类型:
Journal Article
作者: Crawford, Melissa;Batte, Kara;Yu, Lianbo;Wu, Xin;Nuovo, Gerard J.;Marsh, Clay B.;Otterson, Gregory A.;Nana-Sinkam, Serge P.研究方向: Biochemistry & Molecular Biology;BiophysicsMeSH主题词: --
来源链接:pubmed详情页地址

文献摘要

Lung cancer is the most frequent cause of cancer-related death in this country for men and women. MicroRNAs (miRNAs) are a family of small non-coding RNAs (approximately 21–25 nt long) capable of targeting genes for either degradation of mRNA or inhibition of translation. We identified aberrant expression of 41 miRNAs in lung tumor versus uninvolved tissue. MiR-133B had the lowest expression of miRNA in lung tumor tissue (28 fold reduction) compared to adjacent uninvolved tissue. We identified two members of the BCL-2 family of pro-survival molecules (MCL-1 and BCL2L2 (BCLw)) as predicted targets of miR-133B. Selective over-expression of miR-133B in adenocarcinoma (H2009) cell lines resulted in reduced expression of both MCL-1 and BCL2L2. We then confirmed that miR-133B directly targets the 3’UTRs of both MCL-1 and BCL2L2. Lastly, over-expression of miR-133B induced apoptosis following gemcitabine exposure in these tumor cells. To our knowledge, this represents the first observation of decreased expression of miR-133B in lung cancer and that it functionally targets members of the BCL-2 family.
在这个国家,肺癌是男性和女性癌症相关死亡的最常见原因。微小核糖核酸(miRNAs)是一类小分子非编码RNA(长度约为21 - 25个核苷酸),能够针对基因进行信使核糖核酸(mRNA)降解或翻译抑制。我们发现与未受累组织相比,在肺肿瘤中有41种miRNAs表达异常。与相邻的未受累组织相比,miR - 133B在肺肿瘤组织中的表达量最低(降低了28倍)。我们确定了促存活分子BCL - 2家族的两个成员(MCL - 1和BCL2L2(BCLw))是miR - 133B的预测靶点。在腺癌(H2009)细胞系中选择性过表达miR - 133B导致MCL - 1和BCL2L2的表达均降低。然后我们证实miR - 133B直接靶向MCL - 1和BCL2L2的3’非翻译区。最后,在这些肿瘤细胞中,miR - 133B的过表达在吉西他滨暴露后诱导了细胞凋亡。据我们所知,这是首次观察到miR - 133B在肺癌中表达降低,并且它在功能上靶向BCL - 2家族成员。
参考文献(38)
被引文献(144)
The hallmarks of cancer
DOI:
10.1016/s0092-8674(00)81683-9
发表时间:
2000-01-07
期刊:
CELL
影响因子:
64.5
作者:
Hanahan, D;Weinberg, RA
通讯作者:
Weinberg, RA
Cancer Statistics, 2009
DOI:
10.3322/caac.20006
发表时间:
2009-07-01
期刊:
CA-A CANCER JOURNAL FOR CLINICIANS
影响因子:
254.7
作者:
Jemal, Ahmedin;Siegel, Rebecca;Thun, Michael J.
通讯作者:
Thun, Michael J.
Prediction of mammalian microRNA targets
DOI:
10.1016/s0092-8674(03)01018-3
发表时间:
2003-12-26
期刊:
CELL
影响因子:
64.5
作者:
Lewis, BP;Shih, IH;Burge, CB
通讯作者:
Burge, CB
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma
DOI:
10.1001/jama.299.4.425
发表时间:
2008-01-30
期刊:
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
影响因子:
120.7
作者:
Schetter, Aaron J.;Leung, Suet Yi;Harris, Curtis C.
通讯作者:
Harris, Curtis C.
BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line
DOI:
10.1111/j.1349-7006.2007.00491.x
发表时间:
2007-07-01
期刊:
CANCER SCIENCE
影响因子:
5.7
作者:
Kawasaki, Tsutomu;Yokoi, Sana;Inazawa, Johji
通讯作者:
Inazawa, Johji

数据更新时间:{{ references.updateTime }}

关联基金

Regulation of Prostacyclin in Pulmonary Hypertension
批准号:
7480211
批准年份:
2004
资助金额:
13.15
项目类别:
Nana-Sinkam, Serge P.
通讯地址:
Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA
所属机构:
Ohio State UnivnUniversity System of OhionOhio State UniversitynOhio State University Medical CenternThe Ohio State University Wexner Medical Center Department of Pathology
电子邮件地址:
--
通讯地址历史:
DHLRI, Div Pulm Allergy Crit Care & Sleep Med, Columbus, OH 43210 USA
所属机构
DHLRI
University System of Ohio
Ohio State University
Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA
所属机构
Ohio State Univ
University System of Ohio
Ohio State University
Div Hematol & Oncol, Columbus, OH 43210 USA
所属机构
Div Hematol & Oncol
免责声明免责声明
1、猫眼课题宝专注于为科研工作者提供省时、高效的文献资源检索和预览服务;
2、网站中的文献信息均来自公开、合规、透明的互联网文献查询网站,可以通过页面中的“来源链接”跳转数据网站。
3、在猫眼课题宝点击“求助全文”按钮,发布文献应助需求时求助者需要支付50喵币作为应助成功后的答谢给应助者,发送到用助者账户中。若文献求助失败支付的50喵币将退还至求助者账户中。所支付的喵币仅作为答谢,而不是作为文献的“购买”费用,平台也不从中收取任何费用,
4、特别提醒用户通过求助获得的文献原文仅用户个人学习使用,不得用于商业用途,否则一切风险由用户本人承担;
5、本平台尊重知识产权,如果权利所有者认为平台内容侵犯了其合法权益,可以通过本平台提供的版权投诉渠道提出投诉。一经核实,我们将立即采取措施删除/下架/断链等措施。
我已知晓